Genovese Burford & Brothers Wealth & Retirement Plan Management’s Myriad Genetics MYGN Stock Holding History

Genovese Burford & Brothers Wealth & Retirement Plan Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-144	Closed	-$5K	–	258
2018 Q2	$5K	Hold	144	–	–	﹤0.01%	356
2018 Q1	$4K	Hold	144	–	–	﹤0.01%	380
2017 Q4	$6K	Hold	144	–	–	0.02%	198
2017 Q3	$5K	Hold	144	–	–	﹤0.01%	330
2017 Q2	$3K	Hold	144	–	–	﹤0.01%	342
2017 Q1	$3K	Hold	144	–	–	﹤0.01%	382
2016 Q4	$3K	Hold	144	–	–	﹤0.01%	427
2016 Q3	$2K	Hold	144	–	–	﹤0.01%	392
2016 Q2	$4K	Hold	144	–	–	﹤0.01%	334
2016 Q1	$5K	Hold	144	–	–	﹤0.01%	313
2015 Q4	$6K	Buy	+144	New	+$6.08K	﹤0.01%	292

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Genovese Burford & Brothers Wealth & Retirement Plan Management's MYGN Position: Q3 2018 in Review

Genovese Burford & Brothers Wealth & Retirement Plan Management sold out of Myriad Genetics (MYGN) in Q3 2018, closing a stake of 144 shares — an estimated $5K sold.

Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in MYGN in Q4 2015 and held it in 11 quarters. The position peaked at $6K in Q4 2017. 284 funds tracked by Wall St. Rank hold MYGN as of Q3 2018.

Genovese Burford & Brothers Wealth & Retirement Plan Management reported no remaining Myriad Genetics position as of Q3 2018 after selling out during the quarter.
Genovese Burford & Brothers Wealth & Retirement Plan Management sold 144 Myriad Genetics shares in Q3 2018, an estimated $5K.
Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in Myriad Genetics in Q4 2015 and held it in 11 quarters.
Genovese Burford & Brothers Wealth & Retirement Plan Management's Myriad Genetics position peaked at $6K in Q4 2017.
284 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2018.

Based on Genovese Burford & Brothers Wealth & Retirement Plan Management's 13F filing for Q3 2018, filed 13 Nov 2018.